We are proud to share that our Chief Business Development Officer, Natalia Elizalde, was recently featured in the renowned life sciences publication pharmaphorum, where she discusses the latest developments in in-vivo lentiviral vector manufacturing.
The article dives into the unique complexities of producing lentiviral vectors for direct patient administration, highlighting the growing demand for cost-effective, high-titer, and regulatory-compliant manufacturing processes. It also emphasizes the critical role of deep analytical capabilities, robust process design, and technical expertise in meeting the standards of this rapidly advancing field.
At VIVEbiotech, we are proud to be at the forefront of this evolution. With a solid and proven track record in manufacturing lentiviral vectors for in-vivo administration, we provide the expertise, experience, and operational excellence required to support the most demanding gene therapy programs.
Read the full article here: https://pharmaphorum.com/rd/advances-manufacturing-vivo-lentiviral-vectors-challenges-and-solutions